Creative Med Technology Hldgs Stock Price, News & Analysis

Creative Medical Technology Holdings (NASDAQ: CELZ) announced FDA clearance of its Investigational New Drug (IND) application for AlloStem™, the first allogenic cellular therapy targeting Type 1 Diabetes (T1D) in the U.S. This milestone allows for the initiation of clinical trials (CELZ-201), expected to begin patient recruitment in Q1 2023. AlloStem™ utilizes Perinatal Tissue Derived Cells, offering potential benefits in treating T1D, which currently affects 1.6 million Americans. The company is committed to developing innovative immunotherapies to address unmet medical needs.

Creative Medical Technology Holdings (NASDAQ: CELZ) announced the development of an allogenic cell line, AlloStem™, which includes a Master Cell Bank and a Drug Master File. This filing is intended for FDA registration, enhancing the company's immunotherapy and regenerative medicine initiatives. CEO Timothy Warbington emphasized the benefits of internal development over licensing agreements, reducing risk for various therapeutic programs, including those targeting Type 1 diabetes. The Drug Master File will aid in Orphan Drug Development and does not expire, offering a significant advantage in the biotechnology sector.

Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive two-year follow-up results from its StemSpine® study, demonstrating an 87% efficacy rate in treating chronic lower back pain. The procedure, using the patient's bone marrow aspirate, reported no serious adverse effects up to two years post-treatment. The company emphasizes this may help address the opioid crisis by offering a non-surgical option for millions suffering from chronic pain.

Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive results from a three-year follow-up study of its OvaStem® procedure, aimed at treating Primary Ovarian Insufficiency (POI). The study revealed a **90% efficacy** in improving hormonal function and a **70% success rate** in delivering healthy babies using the patients' own eggs. Importantly, there were **no serious adverse effects** reported. This innovative procedure, utilizing the patient's own bone marrow aspirate, represents a potential advancement in fertility treatment for women with POI, who typically face low chances of conception.

Creative Medical Technology Holdings (NASDAQ: CELZ) has signed an agreement with Greenstone Biosciences for the development of a human induced pluripotent stem cell (iPSC) pipeline, termed iPScelzTM, enhancing its ImmCelz® platform. This collaboration aims to leverage Greenstone's expertise in iPSC technology to improve patient care across various conditions such as stroke and diabetes. The agreement signals potential advancements in regenerative medicine, with the iPScelzTM project poised to enable sustainable large-scale production while reducing costs. The partnership is viewed positively by both companies' leadership.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has entered into a securities purchase agreement for a private placement, issuing 7,555,556 shares of common stock priced at $2.25 per share, with gross proceeds expected around $17 million. In addition, the company will issue warrants to purchase up to 15,111,112 shares, exercisable at $2.00 each. The funds will support ongoing clinical studies for their StemSpine® and ImmCelz^TM platforms, among other initiatives. The deal is set to close on or about May 3, 2022.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced advancements in producing its ImmCelz® product, achieving higher volumes in under 72 hours through a novel cell-free supercharging solution. This method consistently maintains the potency of ImmCelz®, which uses adult stem cells to enhance immune response. The company is focusing on stroke first, seeking FDA approval for clinical trials. Future applications may address Type I diabetes, heart, liver, and kidney diseases, signaling strong potential for improving patient outcomes.

Creative Medical Technology Holdings (NASDAQ: CELZ) will showcase its patented CaverStem® procedure at the American Urological Association Annual Meeting on May 13-16, 2022, in New Orleans. This procedure utilizes patients' own stem cells to effectively treat erectile dysfunction. The company highlights landmark clinical trial results published in the Journal of Translational Medicine, demonstrating strong efficacy without major adverse effects. CaverStem® has garnered a growing physician network and offers optimized protocols that reduce costs and streamline treatment.

Creative Medical Technology Holdings (NASDAQ: CELZ) announced a Master Collaboration Agreement with the University of Miami to enhance the ImmCelz® Supercharged Autologous Immunotherapy Platform. This partnership aims to optimize the platform, involving adult stem cells to improve patients' immune response. The company is focusing on advancing therapies for conditions like stroke, type I diabetes, heart, liver, and kidney diseases. ImmCelz® is currently under FDA review for stroke clinical trials. The initiative seeks to accelerate research and clinical translation of promising results.